Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate | Zendy

Joy N. Tsai | Zendy; Yuli Zhu | Zendy; Katelyn Foley | Zendy; Hang Lee | Zendy; SherriAnn M. BurnettBowie | Zendy; Robert M. Neer | Zendy; Benjamin Z. Leder | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate

Author(s) -

Joy N. Tsai,

Yuli Zhu,

Katelyn Foley,

Hang Lee,

SherriAnn M. BurnettBowie,

Robert M. Neer,

Benjamin Z. Leder

Publication year - 2015

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2015-1541

Subject(s) - teriparatide , denosumab , medicine , bone resorption , urology , osteoporosis , resorption , endocrinology , n terminal telopeptide , bone mineral , chemistry , osteocalcin , biochemistry , alkaline phosphatase , enzyme

In postmenopausal osteoporotic women, denosumab fully inhibits teriparatide-induced bone resorption at approved doses. This property of denosumab is distinct from that of alendronate and likely contributes to the efficacy of combination denosumab and teriparatide therapy. Whether denosumab fully inhibits bone resorption when challenged by a higher dose of teriparatide is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research